| scholarly article | Q13442814 |
| P50 | author | François Guérard | Q41027461 |
| P2093 | author name string | Martin W Brechbiel | |
| Jean-François Gestin | |||
| P2860 | cites work | Possible Production of Radioactive Isotopes of Element 85 | Q114769205 |
| Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1 | Q24685212 | ||
| Astatine-211: production and availability | Q27015038 | ||
| Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity | Q33373401 | ||
| Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues | Q33657227 | ||
| Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis | Q33696680 | ||
| Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6 | Q33705446 | ||
| A Comparison of the Metabolism of Iodine and of Element 85 (Eka-Iodine) | Q33745593 | ||
| Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine | Q33925339 | ||
| An overview of targeted alpha therapy | Q34238513 | ||
| The ARRONAX project | Q34243204 | ||
| Towards translation of 212Pb as a clinical therapeutic; getting the lead in! | Q35028126 | ||
| A kit method for the high level synthesis of [211At]MABG. | Q35828025 | ||
| Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25 | Q35849893 | ||
| Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies | Q36154918 | ||
| Polonium-210 as a poison | Q36753205 | ||
| Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies | Q37098874 | ||
| Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab | Q37289402 | ||
| Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice | Q37397869 | ||
| Avidin-biotin technology in targeted therapy | Q37710089 | ||
| Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model | Q39465823 | ||
| Effect of cetuximab in combination with alpha-radioimmunotherapy in cultured squamous cell carcinomas | Q39609849 | ||
| RBE of α-particles from (211)At for complex DNA damage and cell survival in relation to cell cycle position | Q39617950 | ||
| The preparation of astatine labelled proteins using an electrophilic reaction | Q39644687 | ||
| In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapy | Q39686512 | ||
| Synthesis and analysis of 2-[211At]-L-phenylalanine and 4-[211At]-L-phenylalanine and their uptake in human glioma cell cultures in-vitro | Q39742821 | ||
| Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice | Q40080205 | ||
| Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinoma | Q40144418 | ||
| Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2. | Q40201064 | ||
| The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia | Q40243247 | ||
| Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. | Q40249007 | ||
| Preparation and in vivo evaluation of a novel stabilized linker for 211At labeling of protein | Q40276423 | ||
| Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor | Q40328691 | ||
| Targeting against epidermal growth factor receptors. Cellular processing of astatinated EGF after binding to cultured carcinoma cells. | Q40452977 | ||
| Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins. | Q40479496 | ||
| Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers | Q40486298 | ||
| 5-[211 At]astato-2'-deoxyuridine, an alpha particle-emitting endoradiotherapeutic agent undergoing DNA incorporation | Q41215737 | ||
| Alpha-particle radiotherapy with 211At-labeled monodisperse polymer particles, 211At-labeled IgG proteins, and free 211At in a murine intraperitoneal tumor model. | Q41354432 | ||
| Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention | Q41865540 | ||
| Reagents for astatination of biomolecules. 3. Comparison of closo-decaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211. | Q43146282 | ||
| Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac | Q43752162 | ||
| High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. | Q43755984 | ||
| Synthesis and biodistribution of 211At-labeled, biotinylated, and charge-modified poly-L-lysine: evaluation for use as an effector molecule in pretargeted intraperitoneal tumor therapy | Q43992766 | ||
| Preparation of a biologically stable and immunogenically competent astatinated protein | Q44246693 | ||
| N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with alpha-particle emitting 211At | Q44454339 | ||
| (211)At-labeled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L- and poly-D-Lysine as multicarriers | Q44594077 | ||
| Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds | Q44735158 | ||
| Biotin reagents in antibody pretargeting. 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl- and nido-carboranyl-biotin derivatives | Q44900273 | ||
| The preparation of astatine labelled proteins | Q44945823 | ||
| Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles | Q46421518 | ||
| Astatination of nanoparticles containing silver as possible carriers of 211At. | Q46696186 | ||
| Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study. | Q50605886 | ||
| 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. | Q54088537 | ||
| Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy. | Q54146952 | ||
| The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. | Q55478016 | ||
| Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate. | Q55478572 | ||
| Preparation and preliminary evaluation of 4-[211At]astato-N-piperidinoethyl benzamide. | Q55480860 | ||
| Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields | Q56037985 | ||
| Feasibility of the radioastatination of a monoclonal antibody with astatine-211 purified by wet extraction | Q57760552 | ||
| Relative biological effectiveness of the alpha-particle emitter (211)At for double-strand break induction in human fibroblasts | Q64388093 | ||
| 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation | Q67602241 | ||
| Astatine-211 labeling of an antimelanoma antibody and its Fab fragment using N-succinimidyl p-astatobenzoate: comparisons in vivo with the p-[125I]iodobenzoyl conjugate | Q68030808 | ||
| Comparative tissue distribution in mice of the alpha-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 fragment | Q68786765 | ||
| Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate | Q69827531 | ||
| Halogen exchanges using crown ethers: synthesis and preliminary biodistribution of 6-[211At]astatomethyl-19-norcholest-5(10)-en-3 beta-ol | Q69980161 | ||
| Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis | Q71105194 | ||
| Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate | Q72132787 | ||
| Measuring astatine-211 distributions with SPECT | Q72915842 | ||
| Preparation and biological evaluation of an astatine-211 labeled biotin conjugate: biotinyl-3-[211 At]astatoanilide | Q73195202 | ||
| Monoclonal antibody F(ab')2 fragment labeled with N-succinimidyl 2,4-dimethoxy-3-halobenzoates: in vivo comparison of iodinated and astatinated fragments | Q73537057 | ||
| Radioiodination and astatination of octreotide by conjugation labeling | Q74154270 | ||
| Blocking [211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds | Q74696068 | ||
| Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation | Q77456088 | ||
| Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate | Q77925172 | ||
| The induction of tumors in the rat by astatine-211 | Q78347872 | ||
| Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion | Q79733492 | ||
| Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 3: alpha-particle-induced radiolytic effects on the chemical behavior of (211)At | Q80491271 | ||
| Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination | Q80510964 | ||
| Destructive action of astatine 211 (element 85) on the thyroid gland of the rat | Q80663914 | ||
| 211AtCl@US-tube nanocapsules: a new concept in radiotherapeutic-agent design | Q80718213 | ||
| Experimental study of the cross-sections of alpha-particle induced reactions on 209Bi | Q81706665 | ||
| In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin | Q82672455 | ||
| In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction | Q83186913 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 1-20 | |
| P577 | publication date | 2012-10-17 | |
| P1433 | published in | Cancer Biotherapy and Radiopharmaceuticals | Q15766755 |
| P1476 | title | Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy | |
| P478 | volume | 28 |
| Q37722429 | (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy |
| Q92657898 | Advances in targeted alpha therapy for prostate cancer |
| Q47721286 | Bifunctional aryliodonium salts for highly efficient radioiodination and astatination of antibodies. |
| Q58500452 | Experimental and computational evidence of halogen bonds involving astatine |
| Q99602976 | Human dosimetry of free 211At and meta-[211At]astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice |
| Q37390674 | Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer |
| Q34419562 | Radioimmunotherapy with α-particle-emitting radionuclides |
| Q89529826 | Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology |
| Q89798939 | Realizing Clinical Trials with Astatine-211: The Chemistry Infrastructure |
| Q35287836 | Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals |
| Q37085052 | Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle. |
| Q57107703 | Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine |
| Q91105938 | Towards elucidating the radiochemistry of astatine - Behavior in chloroform |
| Q64921914 | Trastuzumab-Modified Gold Nanoparticles Labeled with 211At as a Prospective Tool for Local Treatment of HER2-Positive Breast Cancer. |
| Q41027410 | Unexpected Behavior of the Heaviest Halogen Astatine in the Nucleophilic Substitution of Aryliodonium Salts |
| Q88072959 | α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1 |
Search more.